1
|
Muresanu D. Advances in post stroke neurorehabilitation - From neuro fundamentals to evidence based medicine. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Poon W, Matula C, Vos PE, Muresanu DF, von Steinbüchel N, von Wild K, Hömberg V, Wang E, Lee TMC, Strilciuc S, Vester JC. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci 2019; 41:281-293. [PMID: 31494820 DOI: 10.1007/s10072-019-04053-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2019] [Accepted: 08/19/2019] [Indexed: 12/11/2022]
Abstract
OBJECTIVE To evaluate the safety and efficacy of Cerebrolysin as an add-on therapy to local standard treatment protocol in patients after moderate-to-severe traumatic brain injury. METHODS The patients received the study medication in addition to standard care (50 mL of Cerebrolysin or physiological saline solution daily for 10 days, followed by two additional treatment cycles with 10 mL daily for 10 days) in a prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-centre phase IIIb/IV trial. The primary endpoint was a multidimensional ensemble of 14 outcome scales pooled to be analyzed by means of the multivariate, correlation-sensitive Wei-Lachin procedure. RESULTS In 46 enrolled TBI patients (Cerebrolysin 22, placebo 24), three single outcomes showed stand-alone statistically significant superiority of Cerebrolysin [Stroop Word/Dots Interference (p = 0.0415, Mann-Whitney(MW) = 0.6816, 95% CI 0.51-0.86); Color Trails Tests 1 and 2 (p = 0.0223/0.0170, MW = 0.72/0.73, 95% CI 0.53-0.90/0.54-0.91), both effect sizes lying above the benchmark for "large" superiority (MW > 0.71)]. While for the primary multivariate ensemble, statistical significance was just missed in the intention-to-treat population (pWei-Lachin < 0.1, MWcombined = 0.63, 95% CI 0.48-0.77, derived standardized mean difference (SMD) 0.45, 95% CI -0.07 to 1.04, derived OR 2.1, 95% CI 0.89-5.95), the per-protocol analysis showed a statistical significant superiority of Cerebrolysin (pWei-Lachin = 0.0240, MWcombined = 0.69, 95% CI 0.53 to 0.85, derived SMD 0.69, 95% CI 0.09 to 1.47, derived OR 3.2, 95% CI 1.16 to 12.8), with effect sizes of six single outcomes lying above the benchmark for "large" superiority. Safety aspects were comparable to placebo. CONCLUSION Our trial suggests beneficial effects of Cerebrolysin on outcome after TBI. Results should be confirmed by a larger RCT with a comparable multidimensional approach.
Collapse
Affiliation(s)
- W Poon
- Division of Neurosurgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
| | - C Matula
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - P E Vos
- Department of Neurology, Slingeland Hospital, Doetinchem, The Netherlands
| | - D F Muresanu
- Department of Clinical Neurosciences, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. .,RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 400364, Cluj-Napoca, Romania.
| | - N von Steinbüchel
- Institute of Medical Psychology and Medical Sociology, University Medical Centre Göttingen, Göttingen, Germany
| | - K von Wild
- Medical Faculty, Westphalia Wilhelm's University, Münster, Germany
| | - V Hömberg
- Department of Neurology, SRH Gesundheitszentrum Bad Wimpfen GmbH, Bad Wimpfen, Germany
| | - E Wang
- Department of Neurosurgery, National Neuroscience Institute, Singapore, Singapore
| | - T M C Lee
- State Key Laboratory of Brain and Cognitive Sciences and Laboratory of Neuropsychology, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - S Strilciuc
- Department of Clinical Neurosciences, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.,RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, 400364, Cluj-Napoca, Romania
| | - J C Vester
- Department of Biometry and Clinical Research, idv Data Analysis and Study Planning, Krailling, Germany
| |
Collapse
|
3
|
Toader LE, Rosu GC, Catalin B, Tudorica V, Pirici I, Taisescu O, Muresanu DF. Clinical and Histopathological Assessment on an Animal Model with Experimental Autoimmune Encephalomyelitis. Curr Health Sci J 2018; 44:280-287. [PMID: 30647949 PMCID: PMC6311223 DOI: 10.12865/chsj.44.03.12] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Accepted: 09/10/2018] [Indexed: 01/05/2023]
Abstract
Multiple sclerosis (MS) is a disease of the Central Nervous System (CNS) which alters over 2 million people, and involves an abnormal autoimmune response directed against the brain, nerves and spinal cord. The antigen or the autoimmune target still remains unknown, a fact for which MS is considered to be an immune mediated disease. The pathology involves mainly the white matter, but the gray matter demyelination plays an important role in its pathogenesis. In 80% of the cases with MS, the disease develops relapses. Experimental autoimmune encephalomyelitis (EAE) is the most used model to study MS and for assessing potential treatments. In the present study we report on the histopathological characterization of an EAE model in C57BL/6 mice immunized by injection with myelin oligodendrocyte glycoprotein, MOG35-55 in complete Freud's adjuvant supplemented with pertussis toxin. On a group of 10 immunized animals and on 5 control animals, we followed the development and grading signs of motor deficiency, and after a survival of 34 days, the study aimed to evaluate the histopathological changes in the telencephalon, brainstem, cervical spinal cord, the optic nerve and retina. We utilized histochemistry, immunohistochemistry, and densitometric image analysis methods to assess myelin loss [Luxol fast blue, immunohistochemistry for the presence of microglia (Iba1) and reactive astrocytes (GFAP)]. Moreover, the study includes a first analysis of the detailed histopathological changes of the optic nerve and retina on an EAE model, all of these as the background for testing drugs with potential therapeutic role in MS.
Collapse
Affiliation(s)
- L E Toader
- Department of Neurology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania
| | - G C Rosu
- Department of Research Methodology, University of Medicine and Pharmacy of Craiova, Romania
| | - B Catalin
- Department of Physiology, University of Medicine and Pharmacy of Craiova, Romania
| | - V Tudorica
- Department of Neurology, University of Medicine and Pharmacy of Craiova, Romania
| | - I Pirici
- Department of Human Anatomy, University of Medicine and Pharmacy of Craiova, Romania
| | - O Taisescu
- Department of Human Anatomy, University of Medicine and Pharmacy of Craiova, Romania
| | - D F Muresanu
- Department of Clinical Neurosciences, University of Medicine and Pharmacy "Iuliu Hatieganu" and "RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| |
Collapse
|
4
|
Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life 2017; 10:153-160. [PMID: 29075343 PMCID: PMC5652261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background and Purpose : The aim of this study was to evaluate the efficacy, safety, and tolerability of cerebrolysin in the early recovery phase after acute ischemic stroke. Methods. This prospective, randomized, double-blinded, placebo-controlled, multicenter, parallel-group study enrolled a total of 100 patients within 18 h after the onset of stroke. The patients were treated with Cerebrolysin (30 mL over seven days followed by 10 mL until day 30) or placebo once daily over a period of four weeks. Efficacy was primarily assessed by the NIH Stroke Scale at day 30, and additional parameters included the modified Rankin Scale, the Clinical Global Impression, the Patient Global Satisfaction (PGS) and the Mini Mental State Examination (MMSE). Nonparametric statistical procedures employing the Wilcoxon-Mann-Whitney test were used for data analysis. Safety and tolerability were assessed by adverse events, vital signs, and laboratory parameters. Results.The estimated effect size on the change from baseline in the NIH Stroke Scale on day 30 indicated a medium to large superiority of cerebrolysin compared to placebo (Mann-Whitney [MW] 0.66; 95% confidence interval [CI] 0.55-0.78, P=0.005). Similar effect sizes were reported for the modified Ranking Scale (MW 0.65; 95% CI 0.54-0.76; P=0.010) and the Clinical Global Impression (MW 0.70; 95% CI 0.55-0.85; P=0.006). Effect sizes in the MMSE and PGS did not reach statistical significance. No significant group differences were seen in any of the safety parameters. Conclusions. Cerebrolysin was effective, safe, and well tolerated in the early recovery phase after acute ischemic stroke and significantly improved neurological and global function outcomes compared to placebo.
Collapse
Affiliation(s)
- K Gharagozli
- Department of Neurology, Shahid Beheshti Medical University, Teheran, Islamic Republic of Iran
| | - AA Harandi
- Department of Neurology, Shahid Beheshti Medical University, Teheran, Islamic Republic of Iran
| | - S Houshmand
- Department of Neurology, Shahid Beheshti Medical University, Teheran, Islamic Republic of Iran
| | - N Akbari
- Department of Neurology, Shahid Beheshti Medical University, Teheran, Islamic Republic of Iran
| | - DF Muresanu
- Department of Clinical Neurosciences, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
,RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - J Vester
- Department of Biometry and Clinical Research, IDV Data Analysis and Study Planning, Krailling, Germany
| | - S Winter
- EVER Neuro Pharma GmbH, Unterach, Austria
| | - H Moessler
- COMAMO Lifesciences GmbH, Mondsee, Austria
| |
Collapse
|
5
|
Balta F, Merticariu M, Taban C, Neculau G, Merticariu A, Muresanu D, Badescu D, Jinga V. The remote effects of intravitreal anti-VEGF therapy. J Med Life 2016; 9:392-398. [PMID: 27928444 PMCID: PMC5141400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 09/18/2016] [Indexed: 10/28/2022] Open
Abstract
Objective: To study the effects of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) therapy with Avastin for wet Age-Related Macular Degeneration (AMD) on Benign Prostatic Hyperplasia (BPH)-related symptoms. Methods: An exploratory trial was conducted from August 1, 2013 to February 1, 2014, that included 14 male patients previously diagnosed with BPH, who were aged between 59 and 69 years. The trial was performed in Bucharest and involved two medical institutions: the Clinical Hospital of Eye Emergencies and the "Prof. Dr. Theodor Burghele" Hospital. This prospective study utilized both objective and subjective indicators to analyze the link between intravitreal anti-VEGF therapy for wet AMD and BPH. The evaluations consisted of uroflowmetry and International Prostate Symptom Score (I-PSS) assessments. Results: The maximum flow rate (Qmax) improved by an average of 5.05 ml/ sec in 9 patients, whereas the remaining 5 patients showed a slight decrease in Qmax (mean 1.6 ml/ sec). The I-PSS score improved, with an overall decrease of 1.18 points at follow-up compared to the initial score (mean initial score = 2.42; mean follow-up score = 1.24). Conclusion: The analysis revealed that anti-VEGF therapy for wet AMD had a significant positive effect on all BPH-related symptoms; patients reported improved urinary streams and decreased nocturia. Abbreviations: BPH = benign prostatic hyperplasia, AMD = age-related macular degeneration, VEGF = vascular endothelial growth factor, I-PSS = international prostate symptom score, Qmax = maximum flow rate, TSP-1 = thrombospondin-1, FGF-2 = fibroblast growth factor, mRNA = precursor messenger ribonucleic acid, PSA = prostate-specific antigen, DRE = digital rectal examination, AUR = acute urinary retention, COX2 = cyclooxygenase 2, QoL = quality of life.
Collapse
Affiliation(s)
- F Balta
- Department of Vitreo-Retinal Surgery, Emergency Eye Hospital and Clinic, Bucharest, Romania
| | - M Merticariu
- Department of Urology, "Theodor Burghele" Clinical Hospital, Bucharest, Romania
| | - C Taban
- Department of Vitreo-Retinal Surgery, Emergency Eye Hospital and Clinic, Bucharest, Romania
| | - G Neculau
- Romanian Centre for Economic Modeling
| | - A Merticariu
- Department of Vitreo-Retinal Surgery, Emergency Eye Hospital and Clinic, Bucharest, Romania
| | - D Muresanu
- RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, ; Department of Clinical Neurosciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - D Badescu
- Department of Urology, "Theodor Burghele" Clinical Hospital, Bucharest, Romania
| | - V Jinga
- Department of Urology, "Theodor Burghele" Clinical Hospital, Bucharest, Romania
| |
Collapse
|
6
|
Selejan O, Muresanu DF, Popa L, Muresanu-Oloeriu I, Iudean D, Buzoianu A, Suciu S. Credibility judgments in web page design - a brief review. J Med Life 2016; 9:115-9. [PMID: 27453738 PMCID: PMC4863498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Today, more than ever, knowledge that interfaces appearance analysis is a crucial point in human-computer interaction field has been accepted. As nowadays virtually anyone can publish information on the web, the credibility role has grown increasingly important in relation to the web-based content. Areas like trust, credibility, and behavior, doubled by overall impression and user expectation are today in the spotlight of research compared to the last period, when other pragmatic areas such as usability and utility were considered. Credibility has been discussed as a theoretical construct in the field of communication in the past decades and revealed that people tend to evaluate the credibility of communication primarily by the communicator's expertise. Other factors involved in the content communication process are trustworthiness and dynamism as well as various other criteria but to a lower extent. In this brief review, factors like web page aesthetics, browsing experiences and user experience are considered.
Collapse
Affiliation(s)
- O Selejan
- “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - DF Muresanu
- “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania,Department of Neurosciences, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - L Popa
- “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania,Department of Neurosciences, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - I Muresanu-Oloeriu
- “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| | - D Iudean
- Faculty of Electrical Engineering, Technical University of Cluj-Napoca, Cluj-Napoca, Romania
| | - A Buzoianu
- Department of Clinical Pharmacology and Toxicology, “Iuliu Hatieganu”
University of Medicine and Pharmacy,Cluj-Napoca, Romania
| | - S Suciu
- Department of Functional Biosciences, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
| |
Collapse
|
7
|
Navrotskaya V, Oxenkrug G, Vorobyova L, Sharma H, Muresanu D, Summergrad P. Cerebrolysin Accelerates Metamorphosis and Attenuates Aging-Accelerating Effect of High Temperature in Drosophila Melanogaster. ACTA ACUST UNITED AC 2014; 6:65-68. [PMID: 25798213 DOI: 10.1166/ajnn.2014.1083] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Cerebrolysin® (CBL) is a neuroprotective drug used for the treatment of neurodegenerative diseases. CBL's mechanisms of action remain unclear. Involvement of tryptophan (TRP)-kynurenine (KYN) pathway in neuroprotective effect of CBL might be suggested considering that modulation of KYN pathway of TRP metabolism by CBL, and protection against eclosion defect and prolongation of life span of Drosophila melanogaster with pharmacologically or genetically-induced down-regulation of TRP conversion into KYN. To investigate possible involvement of TRP-KYN pathway in mechanisms of neuroprotective effect of CBL, we evaluated CBL effects on metamorphosis and life span of Drosophila melanogaster maintained at 23 °C and 28 °C ambient temperature. CBL accelerated metamorphosis, exerted strong tendency (p = 0.04) to prolong life span in female but not in male flies, and attenuated aging-accelerating effect of high (28 °C) ambient temperature in both female and male flies. Further research of CBL effects on metamorphosis and resistance to aging-accelerating effect of high temperature might offer new insights in mechanisms of its neuroprotective action and expand its clinical applications.
Collapse
Affiliation(s)
- V Navrotskaya
- Department of Genetics and Cytology, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
| | - G Oxenkrug
- Neuroinflammation Program, Department of Psychiatry, Tufts University/Tufts Medical Center, Boston, MA, USA
| | - L Vorobyova
- Department of Genetics and Cytology, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
| | - H Sharma
- Cerebrovascular Research Laboratory, Department of Surgical Sciences, Anesthesiology and Intensive Care Medicine, University Hospital, Uppsala University, Uppsala, Sweden
| | - D Muresanu
- Department of Neurology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
| | - P Summergrad
- Neuroinflammation Program, Department of Psychiatry, Tufts University/Tufts Medical Center, Boston, MA, USA
| |
Collapse
|
8
|
Brainin M, Muresanu D, Slavoaca D. 2nd International Salzburg Conference on Neurorecovery (ISCN 2013) Salzburg/Austria|November 28th-29th, 2013. J Med Life 2014; 7:458-60. [PMID: 25713602 PMCID: PMC4316118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2014] [Accepted: 10/27/2014] [Indexed: 11/18/2022] Open
Abstract
The 2nd International Salzburg Conference on Neurorecovery was held on the 28th and 29th of November, 2013, in Salzburg, one of the most beautiful cities in Austria, which is well known for its rich cultural heritage, world-famous music and beautiful surrounding landscapes. The aim of the conference was to discuss the progress in the field of neurorecovery. The conference brought together internationally renowned scientists and clinicians, who described the clinical and therapeutic relevance of translational research and its applications in neurorehabilitation.
Collapse
Affiliation(s)
- M Brainin
- Department of Clinical Neurosciences, Donau-Universität Krems, Krems, Austria
| | - D Muresanu
- “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania,“Iuliu Hațieganu” University of Medicine and Pharmacy, Department of Clinical Neurosciences, Cluj-Napoca, Romania
| | - D Slavoaca
- “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania
| |
Collapse
|
9
|
Popa-Wagner A, Buga AM, Popescu B, Muresanu D. Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Transm (Vienna) 2013; 122 Suppl 1:S47-54. [PMID: 24337666 DOI: 10.1007/s00702-013-1129-3] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2013] [Accepted: 11/25/2013] [Indexed: 01/28/2023]
Abstract
To a great extent, cognitive health depends on cerebrovascular health and a deeper understanding of the subtle interactions between cerebrovascular function and cognition is needed to protect humans from one of the most devastating affliction, dementia. However, the underlying biological mechanisms are still not completely clear. Many studies demonstrated that the neurovascular unit is compromised in cerebrovascular diseases and also in other types of dementia. The hemodynamic neurovascular coupling ensures a strong increase of the cerebral blood flow (CBF) and an acute increase in neuronal glucose uptake upon increased neural activity. Dysfunction of cerebral autoregulation with increasing age along with age-related structural and functional alterations in cerebral blood vessels including accumulation of amyloid-beta (Aβ) in the media of cortical arterioles, neurovascular uncoupling due to astrocyte endfeet retraction, impairs the CBF and increases the neuronal degeneration and susceptibility to hypoxia and ischemia. A decreased cerebral glucose metabolism is an early event in Alzheimer's disease (AD) pathology and may precede the neuropathological Aβ deposition associated with AD. Aβ accumulation in turn leads to further decreases in the CBF closing the vicious cycle. Alzheimer, aging and diabetes are also influenced by insulin/insulin-like growth factor-1 signaling, and accumulated evidence indicates sporadic AD is associated with disturbed brain insulin metabolism. Understanding how vascular and metabolic factors interfere with progressive loss of functional neuronal networks becomes essential to develop efficient drugs to prevent cognitive decline in elderly.
Collapse
Affiliation(s)
- A Popa-Wagner
- Department of Psychiatry, University of Medicine, Rostock, Germany,
| | | | | | | |
Collapse
|
10
|
Rakusa M, Gak S, Ehler E, Alekseenko Y, Opara J, Muresanu D, Vos P. Do young European neurologists know enough to comfortably treat patients with neurotrauma? J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.2441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Bianchi S, Di Palma C, Gallus G, Taglia I, Poggiani A, Rosini F, Cerase A, Rufa A, Muresanu D, Dotti M, Federico A. Two new heterozygous mutations of Htra1 gene in a Caucasian patient affected by CARASIL. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.2286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Vos PE, Alekseenko Y, Battistin L, Ehler E, Gerstenbrand F, Muresanu DF, Potapov A, Stepan CA, Traubner P, Vecsei L, von Wild K. Mild traumatic brain injury. Eur J Neurol 2012; 19:191-8. [PMID: 22260187 DOI: 10.1111/j.1468-1331.2011.03581.x] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Traumatic Brain Injury (TBI) is among the most frequent neurological disorders. Of all TBIs 90% are considered mild with an annual incidence of 100–300/100.000. Intracranial complications of Mild Traumatic Brain Injury (MTBI) are infrequent (10%), requiring neurosurgical intervention in a minority of cases (1%), but potentially life-threatening (case fatality rate 0,1%). Hence, a true health management problem exists because of the need to exclude the small chance of a life threatening complication in large numbers of individual patients. The 2002 EFNS guidelines used a best evidence approach based on the literature until 2001 to guide initial management with respect to indications for CT, hospital admission, observation and follow up of MTBI patients. This updated EFNS guideline version for initial management inMTBI proposes a more selectively strategy for CT when major (dangerous mechanism, GCS<15, 2 points deterioration on the GCS, clinical signs of (basal) skull fracture, vomiting, anticoagulation therapy, post traumatic seizure) or minor (age, loss of consciousness, persistent anterograde amnesia, focal deficit, skull contusion, deterioration on the GCS) risk factors are present based on published decision rules with a high level of evidence. In addition clinical decision rules for CT now exist for children as well. Since 2001 recommendations, although with a lower level of evidence, have been published for clinical in hospital observation to prevent and treat other potential threads to the patient including behavioral disturbances (amnesia, confusion and agitation) and infection.
Collapse
Affiliation(s)
- P E Vos
- Radboud University Nijmegen Medical Centre, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Vinţan MA, Palade S, Cristea A, Benga I, Muresanu DF. A neuropsychological assessment, using computerized battery tests (CANTAB), in children with benign rolandic epilepsy before AED therapy. J Med Life 2012; 5:114-9. [PMID: 22574100 PMCID: PMC3307071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Accepted: 01/20/2012] [Indexed: 11/04/2022] Open
Abstract
RATIONALE Benign rolandic epilepsy (BRE) is a form of partial idiopathic epilepsy according to the International League Against Epilepsy (ILAE) syndromes classification (1989). Recent studies have identified cases of BRE that do not meet the initial definition of 'benign'; these included reports of cases with specific cognitive deficits. It is still a matter of debate, whether these deficits are due to epilepsy per se, to treatment or other associated factors. OBJECTIVES The aim of this study was to evaluate if BRE children have cognitive deficits at the onset of their seizures, prior to their participation in any anti-epileptic drug therapy (AED). METHODS AND RESULTS We performed a neuropsychological assessment of 18 BRE children compared with a corresponding age-matched control group. We used the Cambridge Neuropsychological Test Automated Battery (CANTAB). Subjects were at their first neurological evaluation, before any AED therapy. We assessed: visual memory, induction and executive functions. In our group, the BRE children performed comparably with the control children for the induction and executive functions. Substantial differences were identified for the visual memory subtests: PRM percent correct (t = -2.58, p = 0.01) and SRM percent correct (t = -2.73, p = 0.01). Age of seizure onset had a negative impact on the visual memory subtest performances (PRM mean correct latency). We found significant correlations between the different CANTAB subtests results and characteristics of the centrotemporal spikes (CTS). DISCUSSION Our results are consistent with the findings of other similar studies. This form of epilepsy is associated with subtle neuropsychological deficits, present at seizure onset. Neuropsychological deficits identified, suggest a more diffuse brain involvement in the epileptiform process.
Collapse
Affiliation(s)
- MA Vinţan
- “Iuliu Haţieganu” University of Medicine and Pharmacy, Department of Neurosciences, Cluj-Napoca, Romania
,Children’s Hospital, Division of Pediatric Neurology, Cluj-Napoca, Romania
| | - S Palade
- Children’s Hospital, Division of Pediatric Neurology, Cluj-Napoca, Romania
| | - A Cristea
- “Iuliu Haţieganu” University of Medicine and Pharmacy, Department of Neurosciences, Cluj-Napoca, Romania
,Children’s Hospital, Division of Pediatric Neurology, Cluj-Napoca, Romania
| | - I Benga
- “Iuliu Haţieganu” University of Medicine and Pharmacy, Department of Neurosciences, Cluj-Napoca, Romania
,Children’s Hospital, Division of Pediatric Neurology, Cluj-Napoca, Romania
| | - DF Muresanu
- “Iuliu Haţieganu” University of Medicine and Pharmacy, Department of Neurosciences, Cluj-Napoca, Romania
| |
Collapse
|
14
|
Catoi C, von Wild T, von Wild K, Trillenberg P, Heidbreder M, Muresanu D, Mailänder P, Miclaus V, Tabaran F. Neuromodulation after Nerve Grafting into the Spinal Cord in Rats. J Comp Pathol 2012. [DOI: 10.1016/j.jcpa.2011.11.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Marginean IC, Stanca DM, Vacaras V, Soritau O, Margiean M, Muresanu DF. Plasmatic markers in hemorrhagic stroke. J Med Life 2011; 4:148-50. [PMID: 21776296 PMCID: PMC3124268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2010] [Accepted: 04/20/2011] [Indexed: 11/11/2022] Open
Abstract
Stroke is the third most common cause of death in the United States and it is the leading cause of disability. Early diagnosis and immediate therapeutic interventions are important factors to reduce the extent of brain tissue damage and the risk of stroke-related death. A rapid blood test that can confirm the clinical or imaging diagnosis or that can add to the stratification of the risk would be very useful. Such a test has to be validated in large studies and has to be based on a simple and low-cost technology. Many biological markers were tested for their ability to serve as 'would-be' stroke biological markers; some of them appear to have a place in the diagnostic work-up of stroke patients. These molecules include Glial Fibrillary Acidic Protein (GFAP), the N-methyl-D-aspartate receptor (NMDA), APO C-III, APO C-I, PARK7, nucleoside diphosphate kinase A (NDKA), S100B, B-type neurotrophic growth factor, von Willebrand factor, matrix metalloproteinase-9, and monocyte chemotactic protein-1. There are obvious limitations to this study, among them the fact that disability does not necessarily correlate with the amount of cerebral tissue lost (the site of stroke may be more important) and the role of the blood-brain barrier in delaying the release of the neuronal proteins in the blood stream. Further studies are awaited to confirm the role of these molecules in the management of acute stroke patients.
Collapse
Affiliation(s)
- IC Marginean
- Department of Neurology, University of Medicine and Pharmacy, Cluj–NapocaRomania
| | - DM Stanca
- Department of Neurology, University of Medicine and Pharmacy, Cluj–NapocaRomania
| | - V Vacaras
- Department of Neurology, University of Medicine and Pharmacy, Cluj–NapocaRomania
| | - O Soritau
- Department of Cancer Immunology of ‘Prof Dr Ion Chiricuta’ Comprehensive Cancer CenterRomania
| | - M Margiean
- Department of Histology, University of Medicine and Pharmacy, Cluj–NapocaRomania
| | - DF Muresanu
- Department of Neurology, University of Medicine and Pharmacy, Cluj–NapocaRomania
| |
Collapse
|
16
|
Jianu DC, Muresanu DF, Bajenaru O, Popescu BO, Deme SM, Moessler H, Meinzingen SZ, Petrica L, Serpe M, Ursoniu S. Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. J Med Life 2010; 3:297-307. [PMID: 20945821 PMCID: PMC3019000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
BACKGROUND The aim of our study was to assess the efficacy of Cerebrolysin administration in Broca's aphasics with acute ischemic stroke. METHODS We registered 2212 consecutive Broca's aphasics following an acute ischemic stroke admitted in four departments of neurology in Romania, between September 2005 and September 2009. Language was evaluated with the Romanian version of the Western Aphasia Battery (WAB). The following inclusion criteria were used for this study: age 20-75 years, admission in the hospital within 12 hours from the onset of the symptoms, diagnosis of first acute left middle cerebral artery (MCA) ischemic stroke, presence of large artery disease (LAD) stroke, a NIHSS score of 5-22 points, and a therapeutic time window within 72 h. Fifty two patients were treated with Cerebrolysin (Cerebrolysin group) as an adjunctive treatment. A placebo group, which received saline infusions (n=104 patients) were matched to the NIHSS and WAB scores, gender and age of the Cerebrolysin group at baseline. We assessed spontaneous speech (SS), comprehension (C), repetition (R), naming (N), and Aphasia Quotient (AQ) scores of the two groups in an open label design, over 90 days, the mRS scores and mortality. RESULTS The Cerebrolysin and the placebo groups had similar age (66 +/- 8 versus 65 +/- 8 years) and sex ratio (14/38 versus 30/74). The mean AQ scores and the mean subscores for 3 subtests of WAB (SS, R, N) were similar at baseline and improved in the Cerebrolysin group significantly (p < 0.05) over placebo group at all study time points. The mRS score at 90 days was also lower in the Cerebrolysin group than in the placebo group. Cerebrolysin and placebo were both tolerated and safe, and no difference in the mortality rate was seen (3.8% in each group). CONCLUSION Cerebrolysin is effective for the treatment of Broca's aphasics with a first acute ischemic stroke of the left MCA territory.
Collapse
Affiliation(s)
- DC Jianu
- Department of Neurology, ‘Victor Babes’ University of Medicine and Pharmacy,
Clinical Emergency County Hospital, Timisoara
Romania
| | - DF Muresanu
- Department of Neurology, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy Cluj NapocaRomania
| | - O Bajenaru
- Department of Neurology, ‘Carol Davila’ University of Medicine and Pharmacy, University Hospital, BucharestRomania
| | - BO Popescu
- Department of Neurology, ‘Carol Davila’ University of Medicine and Pharmacy, University Hospital, BucharestRomania
| | - SM Deme
- Department of Neurology, ‘Vasile Goldis’ West University AradRomania
| | | | | | - L Petrica
- Department of Internal Medicine, ‘Victor Babes’ University of Medicine and Pharmacy,
Clinical Emergency County Hospital, Timisoara
Romania
| | - M Serpe
- Department of Neurology, ‘Victor Babes’ University of Medicine and Pharmacy,
Clinical Emergency County Hospital, Timisoara
Romania
| | - S Ursoniu
- Department of Internal Medicine, ‘Victor Babes’ University of Medicine and Pharmacy,
Clinical Emergency County Hospital, Timisoara
Romania
| |
Collapse
|
17
|
Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006; 13:43-54. [PMID: 16420392 DOI: 10.1111/j.1468-1331.2006.01222.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Cerebrolysin (Cere) is a compound with neurotrophic activity shown to be effective in Alzheimer's disease in earlier trials. The efficacy and safety of three dosages of Cere were investigated in this randomized, double-blind, placebo-controlled, study. Two hundred and seventy-nine patients were enrolled (69 Cere 10 ml; 70 Cere 30 ml; 71 Cere 60 ml and 69 placebo). Patients received iv infusions of 10, 30, 60 ml Cere or placebo 5 days/week for the first 4 weeks and thereafter, two iv infusions per week for 8 weeks. Effects on cognition and clinical global impressions were evaluated 4, 12 and 24 weeks after the beginning of the infusions using the CIBIC+ and the modified Alzheimer's Disease Assessment Scale (ADAS)-cog. At week 24, significant improvement of cognitive performance on the ADAS-cog (P=0.038) and global function (CIBIC+; P>0.001) was observed for the 10 ml dose. The 30 and 60 ml doses showed significant improvement of the global outcome but failed to show significant improvement of cognition. The results are consistent with a reversed U-shaped dose-response relationship for Cere. The percentage of patients reporting adverse events was similar across all study groups. Cere treatment was well tolerated and led to significant, dose-dependent improvement of cognition and global clinical impression.
Collapse
Affiliation(s)
- X A Alvarez
- Euroespes Biomedical Research Centre, Santa Maria de Babio, Bergondo, La Coruna, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl 2003:277-85. [PMID: 12456070 DOI: 10.1007/978-3-7091-6139-5_25] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
BACKGROUND Cerebrolysin (Cere) is a peptidergic, neurotrophic drug which has been shown to improve cognitive performance and global function of Alzheimer's disease (AD) patients in earlier trials. In this study, we have attempted to replicate this findings with particular emphasis on functional improvement of the patients. PATIENTS AND METHODS Patients received infusions of 30 ml Cere or placebo five days/week for six consecutive weeks. Patients had to have a diagnosis of AD and a MMSE score of 14-25 inclusive. Effects on cognition, global function, and activities of daily living were evaluated 3, 6, and 18 weeks after the beginning of the infusions. RESULTS Significant improvement of cognitive function, clinical global impression and activities of daily living were seen after the end of the therapy. The effects were most pronounced in the DAD score, a measure for the capability to perform activities of daily living. Interestingly, and in line with the findings of earlier studies, the treatment effect of Cere was maintained after cessation of treatment up to the week 18 assessment. CONCLUSION The data confirm the findings of earlier trials and clearly demonstrates that Cere leads to functional improvement of patients with AD. The sustained treatment effect of Cere after withdrawal has been confirmed.
Collapse
Affiliation(s)
- D F Muresanu
- Neurology Department, University of Cluj-Napoca, Cluj-Napoca, Romania
| | | | | |
Collapse
|